AA
EIGR

ALPS Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

ALPS Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,387
Closed -$278K – 995
2021
Q3 		$278K Sell
1,387
-104
-7% -$24.7K ﹤0.01% 874
2021
Q2 		$381K Buy
+1,491
New +$372K ﹤0.01% 610

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ALPS Advisors's EIGR Position: Q4 2021 in Review

ALPS Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2021, closing a stake of 1,387 shares — an estimated $278K sold.

ALPS Advisors first reported a position in EIGR in Q2 2021 and held it in 2 quarters. The position peaked at $381K in Q2 2021. 85 funds tracked by Wall St. Rank hold EIGR as of Q4 2021.

  • ALPS Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • ALPS Advisors sold 1,387 Eiger BioPharmaceuticals, Inc. shares in Q4 2021, an estimated $278K.
  • ALPS Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
  • ALPS Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $381K in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.